Relative risk of pneumonitis or interstitial lung disease (ILD) associated with the use of cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials.

Authors

Nusrat Jahan

Texas Tech University Health Sciences Center, Lubbock, TX

Nusrat Jahan , Sariya Wongsaengsak , Shabnam Rehman , Myrian Vinan-Vega , Lukman Aderoju Tijani , Fred L. Hardwicke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Meta-analysis of cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy versus endocrine therapy alone on progression-free survival (PFS) and overall survival (OS) for metastatic breast cancer (MBC).

First Author: Ranju Kunwor

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.

First Author: Yen-Shen Lu

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis.

First Author: Sara A. Hurvitz

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.

First Author: Takahiro Kogawa